ATP in Lung Endothelial Barrier Enhancement

肺内皮屏障增强中的 ATP

基本信息

  • 批准号:
    7330349
  • 负责人:
  • 金额:
    $ 35.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-01-01 至 2009-12-31
  • 项目状态:
    已结题

项目摘要

ROVIDED. Endothelial cell (EC) barrier dysfunction, a prominent feature of acute lung injury (ALT), is tightly linked to cytoskeletal remodeling, which leads to the disruption of cell-cell contacts and includes activation of contraction initiated by myosin light chain (MLC)phosphorylation followed by F-actin stress fiber formation and formation of paracellular gaps. Little is known about processes which determine barrier enhancement or protection; however, our published data implicate a critical role for cytoskeletal dynamics in this response. Extracellular ATP is an important vascular mediator, which elicits cellular effects on EC mainly through P2Y family receptors coupled to specific trimeric G- proteins. Our novel findings indicate that ATP at physiologically relevant concentrations produces rapid, sustained and dose-dependent increases in transendothelial electrical resistance (TER), indicating profound barrier enhancement and potently reversed barrier dysfunction elicited by the edemagenic agent, thrombin. Specific depletion of a subunits of Gq and Gi2 significantly attenuated ATP-induced increase in TER indicating the involvement of these G-proteins inATP- induced EC barrier enhancement. The ATP-induced increase in TER is tightly linked to an increase in myosin-associated phosphatase (PPase) 1 (MLCP) activity. Inhibition of PPase 1 abolished the ATP-induced increase in TER and lead to phosphorylation of several cytoskeletal targets includingMLC, ezrin/radixin/moezin (ERM) and caldesmon suggesting that dephosphorylation of these proteins may be involved in the barrier-enhancing effect of ATP. In addition, protein kinase A (PKA) inhibition attenuates both ATP-induced increases in TER and phosphorylation of vasolidator- stimulated protein (VASP), which in the phosphorylated form inhibits stress fiber formation supporting the involvement of the PKA/VASP pathway in ATP-induced EC barrier enhancement. Our working hypothesis is that ATP-induced EC barrier enhancement and cytoskeletal remodeling is dependent, at least in part, upon activation of specific P2Y/G protein complexes followed by coordinated activation of MLCP and PKA signaling. SA#1will define the role of specific P2Y/G-protein complexes in the activation of MLCP- and PKA-dependent signaling. SA#2 will define the involvement of MLCP and its cytoskeletal targets in ATP-induced EC barrier enhancement. SA #3 will explore the molecular mechanisms by which PKA activity is involved in ATP-induced EC barrier enhancement focusing on VASP and MLCP as potential PKA targets. SA#4 will characterize the potential barrier-protective effects of ATP in murine models of ALL These studies will provide an understanding of the novel signaling pathways involved in ATP-induced lung EC barrier enhancement and promise new directions and targets for treatment of lung disorders.
已送达。 内皮细胞(EC)屏障功能障碍是急性肺损伤(ALT)的一个突出特征,与以下因素密切相关: 细胞骨架重塑,导致细胞-细胞接触的破坏,包括收缩的激活 由肌球蛋白轻链(MLC)磷酸化引发,随后是F-肌动蛋白应激纤维形成和 细胞间隙对决定屏障增强或保护的过程知之甚少;然而,我们的 已发表的数据暗示了细胞骨架动力学在这种反应中的关键作用。细胞外ATP是重要的 血管介质,其主要通过与特异性三聚体G- proteins.我们的新发现表明,ATP在生理相关浓度下产生快速,持续, 跨内皮电阻(TER)呈剂量依赖性增加,表明屏障显著增强, 有效逆转由水肿剂凝血酶引起的屏障功能障碍。Gq α亚基的特异性缺失 和Gi 2显着减弱ATP诱导的TER增加,表明这些G蛋白参与ATP诱导的TER增加。 诱导EC屏障增强。ATP诱导的TER增加与肌球蛋白相关的 磷酸酶(PPase)1(MLCP)活性。PPase 1的抑制消除了ATP诱导的TER增加,并导致 几种细胞骨架靶点的磷酸化,包括MLC、ezrin/radixin/moezin(ERM)和钙调蛋白, 这些蛋白质的去磷酸化可能参与ATP的屏障增强效应。此外,蛋白质 激酶A(PKA)抑制可减弱ATP诱导的TER增加和血管舒缩剂磷酸化- 刺激蛋白(VASP),其磷酸化形式抑制应力纤维形成,支持参与 PKA/VASP途径在ATP诱导的EC屏障增强中的作用。我们的假设是ATP诱导的EC 屏障增强和细胞骨架重塑至少部分依赖于特异性P2 Y/G的激活, 蛋白质复合物,然后协调激活MLCP和PKA信号传导。SA#1将定义特定 P2 Y/G-蛋白复合物在MLCP和PKA依赖性信号传导的激活中的作用SA#2将定义参与 MLCP及其在ATP诱导的EC屏障增强中的细胞骨架靶点。SA #3将探索分子机制, 其中PKA活性参与ATP诱导的EC屏障增强,重点关注VASP和MLCP作为潜在的PKA 目标的SA#4将描述ATP在ALL小鼠模型中的潜在屏障保护作用。 将提供一个新的信号通路参与ATP诱导的肺EC屏障增强的理解, 为肺部疾病的治疗提供了新的方向和靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALEXANDER D VERIN其他文献

ALEXANDER D VERIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALEXANDER D VERIN', 18)}}的其他基金

HDAC9 nuclear/cytoplasmic shuttling in pulmonary vascular endothelial barrier regulation
HDAC9核/细胞质穿梭在肺血管内皮屏障调节中的作用
  • 批准号:
    10597538
  • 财政年份:
    2022
  • 资助金额:
    $ 35.68万
  • 项目类别:
HDAC9 nuclear/cytoplasmic shuttling in pulmonary vascular endothelial barrier regulation
HDAC9核/细胞质穿梭在肺血管内皮屏障调节中的作用
  • 批准号:
    10446078
  • 财政年份:
    2022
  • 资助金额:
    $ 35.68万
  • 项目类别:
Rac1 Stimulation in Adenosine-Induced Barrier Protection
Rac1 刺激腺苷诱导的屏障保护
  • 批准号:
    8198064
  • 财政年份:
    2011
  • 资助金额:
    $ 35.68万
  • 项目类别:
Mini-plasmin: Pre-Clinical Evaluation of a Novel Thrombolytic Strategy for Stroke
微型纤溶酶:中风新型溶栓策略的临床前评估
  • 批准号:
    8215615
  • 财政年份:
    2011
  • 资助金额:
    $ 35.68万
  • 项目类别:
Endothelial Barrier Protection and Repair in Acute Lung Injury
急性肺损伤中的内皮屏障保护和修复
  • 批准号:
    8690947
  • 财政年份:
    2011
  • 资助金额:
    $ 35.68万
  • 项目类别:
Microtubule involvement in lung endothelial pathobiology
微管参与肺内皮病理学
  • 批准号:
    7347546
  • 财政年份:
    2007
  • 资助金额:
    $ 35.68万
  • 项目类别:
ATP in Lung Endothelial Barrier Enhancement
肺内皮屏障增强中的 ATP
  • 批准号:
    7026844
  • 财政年份:
    2006
  • 资助金额:
    $ 35.68万
  • 项目类别:
ATP in Lung Endothelial Barrier Enhancement
肺内皮屏障增强中的 ATP
  • 批准号:
    7540426
  • 财政年份:
    2006
  • 资助金额:
    $ 35.68万
  • 项目类别:
ATP in Lung Endothelial Barrier Enhancement
肺内皮屏障增强中的 ATP
  • 批准号:
    7435762
  • 财政年份:
    2006
  • 资助金额:
    $ 35.68万
  • 项目类别:
ALK/SMAD Signaling in TGF beta-induced EC Permeability
TGFβ 诱导的 EC 通透性中的 ALK/SMAD 信号转导
  • 批准号:
    7446642
  • 财政年份:
    2005
  • 资助金额:
    $ 35.68万
  • 项目类别:

相似海外基金

How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y004841/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.68万
  • 项目类别:
    Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
  • 批准号:
    BB/Y001427/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.68万
  • 项目类别:
    Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y005414/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.68万
  • 项目类别:
    Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
  • 批准号:
    10669829
  • 财政年份:
    2023
  • 资助金额:
    $ 35.68万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10587090
  • 财政年份:
    2023
  • 资助金额:
    $ 35.68万
  • 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
  • 批准号:
    10821599
  • 财政年份:
    2023
  • 资助金额:
    $ 35.68万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10841832
  • 财政年份:
    2023
  • 资助金额:
    $ 35.68万
  • 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
  • 批准号:
    10532480
  • 财政年份:
    2022
  • 资助金额:
    $ 35.68万
  • 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
  • 批准号:
    10741261
  • 财政年份:
    2022
  • 资助金额:
    $ 35.68万
  • 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
  • 批准号:
    10674894
  • 财政年份:
    2022
  • 资助金额:
    $ 35.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了